Compile Data Set for Download or QSAR
maximum 50k data
Found 10 Enz. Inhib. hit(s) with Target = 'Mu-type opioid receptor' and Ligand = 'BDBM50194264'
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.260nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.300nMAssay Description:Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.300nMAssay Description:Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.300nMAssay Description:Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataKi:  0.300nMAssay Description:Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataIC50:  3.5nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataIC50:  150nMAssay Description:Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataIC50:  150nMAssay Description:Antagonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as inhibition of DAMGO induced [35S]GTP-gamma-S bindingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataIC50:  150nMAssay Description:Antagonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding after 6...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50194264((+/-)-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-...)
Affinity DataEC50:  0.850nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US Patent